Company Directory - SWOT Analysis

Pharmaceutical Preparation Manufacturing (325412) Companies

All locations

Company Sector & Purpose Updated Following
AbbVie logo
Biopharmaceutical
To discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow
2025-Q2
Abbott Laboratories logo
Healthcare
To help people live their best possible life through the power of health
2025-Q3
Alnylam Pharmaceuticals logo
Biotechnology
To transform the lives of people afflicted with rare genetic diseases by translating RNA interference into a whole new class of innovative medicines
2025-Q3
Aldeyra Therapeutics logo
Biotechnology
To discover, develop and commercialize novel therapies to treat immune-mediated diseases
2025-Q3
Acadia Pharmaceuticals logo
Biopharmaceuticals
To advance breakthrough medicines that meaningfully improve the lives of patients with central nervous system disorders
2025-Q3
Agios Pharmaceuticals logo
Biopharmaceutical
To transform the lives of patients with genetically defined diseases through scientific leadership in cellular metabolism
2025-Q3
Anika Therapeutics logo
Biotechnology
To develop and commercialize therapeutic products for tissue protection, healing, and repair
2025-Q3
Akebia Therapeutics logo
Biopharmaceutical
To better the lives of people impacted by kidney disease by advancing innovative therapies
2025-Q3
Amphastar Pharmaceuticals logo
Specialty Pharmaceuticals
To develop, manufacture, and market generic and proprietary injectable, inhalation, and intranasal pharmaceutical products
2025-Q3
Alector logo
Biotechnology
To develop innovative immunotherapies for neurodegenerative diseases by harnessing the brain's immune system
2025-Q3
Ani Pharmaceuticals logo
Specialty Pharmaceuticals
To develop, manufacture and market branded and generic prescription pharmaceuticals
2025-Q3
Alkermes logo
Biopharmaceuticals
To develop innovative medicines that make a difference for people living with debilitating diseases
2025-Q3
Anaptysbio logo
Biotechnology
To discover, develop and deliver innovative immunology therapeutics for patients with serious immune-mediated diseases
2025-Q3
4d Molecular Therapeutics logo
Biotechnology
To transform medicine by advancing next-generation gene therapies using novel AAV vectors to treat genetic diseases
2025-Q3
Amneal Pharmaceuticals logo
Generic Pharmaceuticals
To make healthy possible by providing high-quality, affordable generic and specialty pharmaceuticals to improve patient access to essential medications
2025-Q3
Annexon logo
Biotechnology
To develop innovative complement-targeted therapeutics for patients with classical complement-mediated autoimmune and neurodegenerative diseases
2025-Q3
Anavex Life Sciences logo
Biopharmaceutical
Develop precision medicine therapies targeting sigma-1 receptor for neurodegenerative diseases
2025-Q3
89bio logo
Biotechnology
To develop innovative therapies for patients with liver and cardio-metabolic diseases
2025-Q3
Akero Therapeutics logo
Biotechnology
To develop and commercialize transformational treatments for patients with serious metabolic diseases
2025-Q3
Alumis logo
Biotechnology
To develop transformative medicines for autoimmune and inflammatory diseases through precision targeting of key immune pathways
2025-Q3
AbbVie logo
Biopharmaceutical
To discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow
2025-Q2
Tap to view analysis
Abbott Laboratories logo
Healthcare
To help people live their best possible life through the power of health
2025-Q3
Tap to view analysis
Alnylam Pharmaceuticals logo
Biotechnology
To transform the lives of people afflicted with rare genetic diseases by translating RNA interference into a whole new class of innovative medicines
2025-Q3
Tap to view analysis
Aldeyra Therapeutics logo
Biotechnology
To discover, develop and commercialize novel therapies to treat immune-mediated diseases
2025-Q3
Tap to view analysis
Acadia Pharmaceuticals logo
Biopharmaceuticals
To advance breakthrough medicines that meaningfully improve the lives of patients with central nervous system disorders
2025-Q3
Tap to view analysis
Agios Pharmaceuticals logo
Biopharmaceutical
To transform the lives of patients with genetically defined diseases through scientific leadership in cellular metabolism
2025-Q3
Tap to view analysis
Anika Therapeutics logo
Biotechnology
To develop and commercialize therapeutic products for tissue protection, healing, and repair
2025-Q3
Tap to view analysis
Akebia Therapeutics logo
Biopharmaceutical
To better the lives of people impacted by kidney disease by advancing innovative therapies
2025-Q3
Tap to view analysis
Amphastar Pharmaceuticals logo
Specialty Pharmaceuticals
To develop, manufacture, and market generic and proprietary injectable, inhalation, and intranasal pharmaceutical products
2025-Q3
Tap to view analysis
Alector logo
Biotechnology
To develop innovative immunotherapies for neurodegenerative diseases by harnessing the brain's immune system
2025-Q3
Tap to view analysis
Ani Pharmaceuticals logo
Specialty Pharmaceuticals
To develop, manufacture and market branded and generic prescription pharmaceuticals
2025-Q3
Tap to view analysis
Alkermes logo
Biopharmaceuticals
To develop innovative medicines that make a difference for people living with debilitating diseases
2025-Q3
Tap to view analysis
Anaptysbio logo
Biotechnology
To discover, develop and deliver innovative immunology therapeutics for patients with serious immune-mediated diseases
2025-Q3
Tap to view analysis
4d Molecular Therapeutics logo
Biotechnology
To transform medicine by advancing next-generation gene therapies using novel AAV vectors to treat genetic diseases
2025-Q3
Tap to view analysis
Amneal Pharmaceuticals logo
Generic Pharmaceuticals
To make healthy possible by providing high-quality, affordable generic and specialty pharmaceuticals to improve patient access to essential medications
2025-Q3
Tap to view analysis
Annexon logo
Biotechnology
To develop innovative complement-targeted therapeutics for patients with classical complement-mediated autoimmune and neurodegenerative diseases
2025-Q3
Tap to view analysis
Anavex Life Sciences logo
Biopharmaceutical
Develop precision medicine therapies targeting sigma-1 receptor for neurodegenerative diseases
2025-Q3
Tap to view analysis
89bio logo
Biotechnology
To develop innovative therapies for patients with liver and cardio-metabolic diseases
2025-Q3
Tap to view analysis
Akero Therapeutics logo
Biotechnology
To develop and commercialize transformational treatments for patients with serious metabolic diseases
2025-Q3
Tap to view analysis
Alumis logo
Biotechnology
To develop transformative medicines for autoimmune and inflammatory diseases through precision targeting of key immune pathways
2025-Q3
Tap to view analysis

Page 1 of 2

Showing 1 to 20 of 34 analyses